沃森生物肺炎疫苗获约旦《药品注册证》

Core Viewpoint - Watson Bio has made significant progress in its strategic layout in the Middle East by obtaining a drug registration certificate for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Jordan Food and Drug Administration [1] Group 1 - The vaccine produced by Watson Bio's subsidiary, Yuxi Watson Bio Technology Co., Ltd., has received the drug registration certificate in Jordan [1] - This marks an important breakthrough in the internationalization process of Watson Bio's 13-valent pneumococcal polysaccharide conjugate vaccine [1] - The actual market launch time and sales performance of the vaccine in Jordan remain uncertain [1]